These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 19805105)

  • 1. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.
    Mandelker D; Gabelli SB; Schmidt-Kittler O; Zhu J; Cheong I; Huang CH; Kinzler KW; Vogelstein B; Amzel LM
    Proc Natl Acad Sci U S A; 2009 Oct; 106(40):16996-7001. PubMed ID: 19805105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.
    Echeverria I; Liu Y; Gabelli SB; Amzel LM
    FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.
    Hon WC; Berndt A; Williams RL
    Oncogene; 2012 Aug; 31(32):3655-66. PubMed ID: 22120714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.
    Huang CH; Mandelker D; Gabelli SB; Amzel LM
    Cell Cycle; 2008 May; 7(9):1151-6. PubMed ID: 18418043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).
    Burke JE; Perisic O; Masson GR; Vadas O; Williams RL
    Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15259-64. PubMed ID: 22949682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha ). Functions of lipid kinase-deficient PI3Kalpha in signaling.
    Pirola L; Zvelebil MJ; Bulgarelli-Leva G; Van Obberghen E; Waterfield MD; Wymann MP
    J Biol Chem; 2001 Jun; 276(24):21544-54. PubMed ID: 11278889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biophysical aspect of phosphatidylinositol 3-kinase and role of oncogenic mutants (E542K & E545K).
    Kalsi N; Gopalakrishnan C; Rajendran V; Purohit R
    J Biomol Struct Dyn; 2016 Dec; 34(12):2711-2721. PubMed ID: 26646651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.
    Huang CH; Mandelker D; Schmidt-Kittler O; Samuels Y; Velculescu VE; Kinzler KW; Vogelstein B; Gabelli SB; Amzel LM
    Science; 2007 Dec; 318(5857):1744-8. PubMed ID: 18079394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα.
    Liu X; Zhou Q; Hart JR; Xu Y; Yang S; Yang D; Vogt PK; Wang MW
    Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2215621119. PubMed ID: 36343266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit.
    Miled N; Yan Y; Hon WC; Perisic O; Zvelebil M; Inbar Y; Schneidman-Duhovny D; Wolfson HJ; Backer JM; Williams RL
    Science; 2007 Jul; 317(5835):239-42. PubMed ID: 17626883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.
    Sun M; Hillmann P; Hofmann BT; Hart JR; Vogt PK
    Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15547-52. PubMed ID: 20713702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.
    Zhao L; Vogt PK
    Cell Cycle; 2010 Feb; 9(3):596-600. PubMed ID: 20009532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design.
    Chen P; Deng YL; Bergqvist S; Falk MD; Liu W; Timofeevski S; Brooun A
    Protein Sci; 2014 Oct; 23(10):1332-40. PubMed ID: 25043846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains.
    Yu J; Wjasow C; Backer JM
    J Biol Chem; 1998 Nov; 273(46):30199-203. PubMed ID: 9804776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in
    Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capitalizing on tumor genotyping: towards the design of mutation specific inhibitors of phosphoinsitide-3-kinase.
    Gabelli SB; Duong-Ly KC; Brower ET; Amzel LM
    Adv Enzyme Regul; 2011; 51(1):273-9. PubMed ID: 21035489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant.
    Gkeka P; Evangelidis T; Pavlaki M; Lazani V; Christoforidis S; Agianian B; Cournia Z
    PLoS Comput Biol; 2014 Oct; 10(10):e1003895. PubMed ID: 25340423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase.
    Dbouk HA; Pang H; Fiser A; Backer JM
    Proc Natl Acad Sci U S A; 2010 Nov; 107(46):19897-902. PubMed ID: 21030680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.
    Hao Y; Wang C; Cao B; Hirsch BM; Song J; Markowitz SD; Ewing RM; Sedwick D; Liu L; Zheng W; Wang Z
    Cancer Cell; 2013 May; 23(5):583-93. PubMed ID: 23643389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis of nSH2 regulation and lipid binding in PI3Kα.
    Miller MS; Schmidt-Kittler O; Bolduc DM; Brower ET; Chaves-Moreira D; Allaire M; Kinzler KW; Jennings IG; Thompson PE; Cole PA; Amzel LM; Vogelstein B; Gabelli SB
    Oncotarget; 2014 Jul; 5(14):5198-208. PubMed ID: 25105564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.